Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program
Business Wire•16/11/2026•08:32 ET
0
Key Highlights
- ➤Loss per share narrowed to $0.13 from $3.06 year-over-year
- ➤Cash and equivalents rose to $6.96 million from $4.98 million year-end 2025
- ➤VT-1953 advanced toward FDA Type C meeting with additional information requested
- ➤Third-quarter net loss declined to $930,325 from $8.60 million year-over-year
- ➤VT-1908 patent claims received USPTO Notice of Allowance in October 2026
Expert Statements
Krishna Gupta, Chairman of Vyome Holdings
“During the third quarter, Vyome continued to concentrate resources on the development of its lead program, VT-1953, while maintaining financial discipline and progressing selected activities across its pipeline. The Company ended September with approximately $7.0 million in cash and cash equivalents. Our emphasis remains on advancing defined development priorities and managing capital carefully.”
Venkat Nelabhotla, President and Chief Executive Officer of Vyome Holdings
“Our immediate priority remains VT-1953. During the quarter, we continued product development, CMC activities, clinical development planning, and preparatory work with prospective GMP manufacturing partners. Following the FDA’s written feedback on our pre-IND briefing package, we have continued assembling the scientific, CMC, and clinical information required to support further discussion with the FDA through a Type C meeting before advancing our proposed clinical development program.”
Venkat Nelabhotla, President and Chief Executive Officer of Vyome Holdings
“We are also reviewing the FDA’s request for additional information and clarification relating to our VT-1953 Orphan Drug Designation application and preparing our response, including any necessary amendment. In parallel, formulation and CMC work continued for our VT-1908 topical ophthalmic program. We remain focused on the progression of our investigational programs and on selective opportunities within immuno-inflammatory disease, while making development and capital allocation decisions based on available data.”
Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program
* Loss per share narrows to $0.13 from $3.06 year-over-year, reflecting significantly lower reported losses, including the impact of substantial merger-related expenses in the prior-year quarter and changes in weighted-average shares outstanding.
Get started
Create a free account to read the full story.
